Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Equillium Inc (NQ: EQ ) 1.089 -0.041 (-3.63%) Streaming Delayed Price Updated: 11:14 AM EDT, Oct 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 59,865 Open 1.140 Bid (Size) 1.050 (78) Ask (Size) 1.090 (1) Prev. Close 1.130 Today's Range 1.054 - 1.140 52wk Range 0.4500 - 3.250 Shares Outstanding 34,414,149 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer October 07, 2024 From Equillium, Inc. Via Business Wire Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit September 10, 2024 From Equillium, Inc. Via Business Wire Performance YTD +48.30% +48.30% 1 Month +28.12% +28.12% 3 Month +26.11% +26.11% 6 Month -34.00% -34.00% 1 Year +86.50% +86.50% More News Read More Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 04, 2024 From Equillium, Inc. Via Business Wire Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference August 28, 2024 From Equillium, Inc. Via Business Wire EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024 August 09, 2024 Via InvestorPlace Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights August 08, 2024 From Equillium Inc. Via Business Wire Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease August 06, 2024 From Equillium, Inc. Via Business Wire Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance July 18, 2024 From Equillium, Inc. Via Business Wire Equillium to Participate in Upcoming Investor Conferences July 02, 2024 From Equillium, Inc. Via Business Wire Equillium to be included in the Russell Microcap® Index June 12, 2024 From Equillium, Inc. Via Business Wire Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 05, 2024 From Equillium, Inc. Via Business Wire Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings June 04, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session June 04, 2024 Via Benzinga Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data June 04, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session June 04, 2024 Via Benzinga Gold Down 1%; Bath & Body Works Shares Tumble After Q1 Results June 04, 2024 Via Benzinga US Stocks Lower; Donaldson Earnings Beat Views June 04, 2024 Via Benzinga Topics Earnings Exposures Financial Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata June 04, 2024 From Equillium Inc. Via Business Wire Equillium to Present at the Jefferies Global Healthcare Conference May 29, 2024 From Equillium, Inc. Via Business Wire Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease May 14, 2024 From Equillium, Inc. Via Business Wire EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights May 09, 2024 From Equillium Inc. Via Business Wire Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists May 07, 2024 From Equillium, Inc. Via Business Wire Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 03, 2024 From Equillium, Inc. Via Business Wire Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis April 01, 2024 From Equillium, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
